GlassScriptPhysician profile
Mark A Moseley
NPI 1740441005
$1,250.08
in general payments reported to CMS, 2019-2025
16 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $60.76 · 2021: $186 · 2022: $334 · 2023: $270 · 2024: $90.79 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $356.48 | 2021-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Abbvie INC. | $151.81 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.98 | 2020-2025 | Ofev |
| Insmed, INC. | $94.25 | 2022-2024 | Arikayce |
| Livanova USA, INC. | $88.85 | 2022 | |
| Genentech USA, INC. | $63.85 | 2019-2025 | Tecentriq |
| Astrazeneca Pharmaceuticals LP | $59.16 | 2023-2025 | Imfinzi, Fasenra |
| Allergan, INC. | $54.65 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52.85 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $43.69 | 2019-2021 | |
| Amgen INC. | $39.01 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $26.71 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $26.13 | 2022 | |
| 3b Medical, INC. | $22.04 | 2025 | Luna |
| Pharmacosmos Therapeutics INC. | $18.49 | 2024 | Cosela |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Moseley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.